Analysis of factors influencing the clinical efficacy of Budigerford inhalation aerosol in the treatment of chronic obstructive pulmonary disease in stable stage
Objective:To investigate the key factors affecting the therapeutic effect of budigerfo inhalation aerosol in the stable period of chronic obstructive pulmonary disease(COPD).Methods:60 patients with stable COPD treated in Ningdu County Hospital of Traditional Chinese Medicine from July 2022 to October 2023 were selected as the study objects.The patients were divided into effective group and ineffective group according to the efficacy after 3 months of treatment with Budigerfo inhalation aerosol.The general data,disease status and laboratory indicators of the two groups were compared,and the factors that might affect the clinical efficacy were analyzed by multivariate Logistic analysis.Results:After treatment,the pH value and PaO2 level of COPD patients increased,and the PaCO2 level decreased,with statistical significance(P<0.05).Of the 60 patients,44 were in the effective group and 16 were in the ineffective group.There were significant differences in COPD grade,smoking history,duration of acute exacerbation,6-minute walking distance(6MWD),modified British Medical Association dyspnea Index(mMRC),COPD assessment test(CAT)score,arterial blood oxygen partial pressure and arterial blood carbon dioxide partial pressure between the two groups(P<0.05).Among them,smoking history,duration of acute exacerbation,6MWD,mMRC score,CAT score and arterial blood oxygen partial pressure were independent influencing factors of budegforo efficacy.Conclusion:The use of budigerfo inhalation aerosol can significantly reduce the clinical symptoms of stable COPD patients,improve their quality of life and daily activities.
NETL
NSTL
万方数据
维普
